Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
2013 1
2015 1
2016 1
2017 2
2018 2
2019 1
2020 1
2021 2
2022 4
2023 2
2024 1
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone.
Choi EM, Lacarra B, Afolabi MO, Ale BM, Baiden F, Bétard C, Foster J, Hamzé B, Schwimmer C, Manno D, D'Ortenzio E, Ishola D, Keita CM, Keshinro B, Njie Y, van Dijck W, Gaddah A, Anumendem D, Lowe B, Vatrinet R, Lawal BJ, Otieno GT, Samai M, Deen GF, Swaray IB, Kamara AB, Kamara MM, Diagne MA, Kowuor D, McLean C, Leigh B, Beavogui AH, Leyssen M, Luhn K, Robinson C, Douoguih M, Greenwood B, Thiébaut R, Watson-Jones D; EBOVAC-3/EBL2005 Study Team. Choi EM, et al. Lancet Glob Health. 2023 Nov;11(11):e1743-e1752. doi: 10.1016/S2214-109X(23)00410-2. Lancet Glob Health. 2023. PMID: 37858585 Free article. Clinical Trial.
Characterization of the Structural Requirements for the NADase Activity of Bacterial Toll/IL-1R domains in a Course-based Undergraduate Research Experience.
Vallejo-Schmidt T, Palm C, Obiorah T, Koudjra AR, Schmidt K, Scudder AH, Guzman-Cruz E, Ingram LP, Erickson BC, Akingbehin V, Riddick T, Hamilton S, Riaz T, Alexander Z, Anderson JT, Bader C, Calkins PH, Chaudhry SS, Collins H, Conteh M, Dada TA, David J, Fallah D, De Leon R, Duff R, Eromosele IR, Jones JK, Keshmiri N, Mercanti MA, Onwezi-Nwugwo J, Ojo MA, Pascoe ER, Poteat AM, Price SE, Riedlbauer D, Rolle LTA, Shoemaker P, Stefano A, Sterling MK, Sultana S, Toneygay L, Williams AN, Nallar S, Weldon JE, Snyder GA, Snyder MLD. Vallejo-Schmidt T, et al. Among authors: conteh m. Immunohorizons. 2024 Aug 1;8(8):563-576. doi: 10.4049/immunohorizons.2300062. Immunohorizons. 2024. PMID: 39172026 Free PMC article.
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial.
Afolabi MO, Ishola D, Manno D, Keshinro B, Bockstal V, Rogers B, Owusu-Kyei K, Serry-Bangura A, Swaray I, Lowe B, Kowuor D, Baiden F, Mooney T, Smout E, Köhn B, Otieno GT, Jusu M, Foster J, Samai M, Deen GF, Larson H, Lees S, Goldstein N, Gallagher KE, Gaddah A, Heerwegh D, Callendret B, Luhn K, Robinson C, Greenwood B, Leyssen M, Douoguih M, Leigh B, Watson-Jones D; EBL3001 study group. Afolabi MO, et al. Lancet Infect Dis. 2022 Jan;22(1):110-122. doi: 10.1016/S1473-3099(21)00128-6. Epub 2021 Sep 13. Lancet Infect Dis. 2022. PMID: 34529962 Free PMC article. Clinical Trial.
Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trial.
Manno D, Bangura A, Baiden F, Kamara AB, Ayieko P, Kallon J, Foster J, Conteh M, Connor NE, Koroma B, Njie Y, Borboh P, Keshinro B, Lawal BJ, Kroma MT, Otieno GT, Deen AT, Choi EM, Balami AD, Gaddah A, McLean C, Luhn K, Adetola HH, Deen GF, Samai M, Lowe B, Robinson C, Leigh B, Greenwood B, Watson-Jones D. Manno D, et al. Among authors: conteh m. Lancet Infect Dis. 2023 Mar;23(3):352-360. doi: 10.1016/S1473-3099(22)00594-1. Epub 2022 Oct 20. Lancet Infect Dis. 2023. PMID: 36273490 Free article. Clinical Trial.
Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.
Ishola D, Manno D, Afolabi MO, Keshinro B, Bockstal V, Rogers B, Owusu-Kyei K, Serry-Bangura A, Swaray I, Lowe B, Kowuor D, Baiden F, Mooney T, Smout E, Köhn B, Otieno GT, Jusu M, Foster J, Samai M, Deen GF, Larson H, Lees S, Goldstein N, Gallagher KE, Gaddah A, Heerwegh D, Callendret B, Luhn K, Robinson C, Leyssen M, Greenwood B, Douoguih M, Leigh B, Watson-Jones D; EBL3001 study group. Ishola D, et al. Lancet Infect Dis. 2022 Jan;22(1):97-109. doi: 10.1016/S1473-3099(21)00125-0. Epub 2021 Sep 13. Lancet Infect Dis. 2022. PMID: 34529963 Free PMC article. Clinical Trial.
Primary Care 2030: Creating an Enabling Ecosystem for Disruptive Primary Care Models to Achieve Universal Health Coverage in Low- and Middle-Income Countries.
Schwarz D, Duong D, Adam C, Awoonor-Williams JK, Back D, Bang A, Bang R, Beebe M, Bhatt S, Campbell J, Conteh M, Dimitrova D, Dimovska D, Dossou JP, Evans T, Gadir M, Islam K, Kasyaba R, Kumar P, Levy C, Oanh TM, Monsef N, Oh J, Otoo N, Palazuelos D, Poh A, Sinha S, Smith C, Stewart B, Thomas C, Tritter B, Varnum P, Weilnau T, Ellner A. Schwarz D, et al. Among authors: conteh m. Ann Glob Health. 2020 Feb 3;86(1):9. doi: 10.5334/aogh.2471. Ann Glob Health. 2020. PMID: 32064227 Free PMC article.
17 results